Ornithine
- Generic Name
- Ornithine
- Brand Names
- Primene
- Drug Type
- Small Molecule
- Chemical Formula
- C5H12N2O2
- CAS Number
- 70-26-8
- Unique Ingredient Identifier
- E524N2IXA3
- Background
Produced during the urea cycle, ornithine is an amino acid produced from the splitting off of urea from arginine. L-Ornithine allows for the disposal of excess nitrogen and acts as a precursor of citrulline and arginine.
- Indication
Used for nutritional supplementation, also for treating dietary shortage or imbalance. It has been claimed that ornithine improves athletic performance, has anabolic effects, has wound-healing effects, and is immuno-enhancing.
- Associated Conditions
- Hepatic Encephalopathy (HE)
- Associated Therapies
- Amino acid supplementation
Anaplerotic Therapy in Propionic Acidemia
- Conditions
- Propionic Acidemia
- Interventions
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- Nicola Longo
- Target Recruit Count
- 3
- Registration Number
- NCT00645879
- Locations
- 🇺🇸
University of Utah, Department of Pediatrics, Salt Lake City, Utah, United States
Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure
- Conditions
- Acute Liver Failure
- First Posted Date
- 2007-05-07
- Last Posted Date
- 2008-01-07
- Lead Sponsor
- All India Institute of Medical Sciences, New Delhi
- Target Recruit Count
- 150
- Registration Number
- NCT00470314
- Locations
- 🇮🇳
All India Institute of Medical Sciences, Delhi, India
Efficacy of L-Ornithine-L-Aspartate in Cirrhotics With Hepatic Encephalopathy
- Conditions
- Hepatic Encephalopathy
- First Posted Date
- 2007-02-09
- Last Posted Date
- 2007-02-09
- Lead Sponsor
- Aga Khan University
- Target Recruit Count
- 108
- Registration Number
- NCT00433368
- Locations
- 🇵🇰
Aga Khan University Hospital, Karachi, Sind, Pakistan
Brain Imaging in Patients With Chronic Liver Disease and Functional Impairment.
- Conditions
- CirrhosisHepatic Encephalopathy
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 50
- Registration Number
- NCT00305591
- Locations
- 🇬🇧
Imperial College London, Hammersmith, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.